Cargando…

BET Inhibition Improves NASH and Liver Fibrosis

Non-alcoholic fatty liver disease (NAFLD) is a leading form of chronic liver disease with large unmet need. Non-alcoholic steatohepatitis (NASH), a progressive variant of NAFLD, can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. To identify potential new therapeutics for NASH, we used a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Middleton, Sarah A., Rajpal, Neetu, Cutler, Leanne, Mander, Palwinder, Rioja, Inmaculada, Prinjha, Rab K., Rajpal, Deepak, Agarwal, Pankaj, Kumar, Vinod
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250695/ https://www.ncbi.nlm.nih.gov/pubmed/30467325 http://dx.doi.org/10.1038/s41598-018-35653-4

Ejemplares similares

Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells
por: Fu, Wenxian, et al.
Publicado: (2014)

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease
por: Elfiky, Ahmed M. I., et al.
Publicado: (2022)

N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
por: Nord, Joshua A., et al.
Publicado: (2022)

Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease
por: Reisdorf, William C., et al.
Publicado: (2019)

Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis
por: Luque-Martin, Rosario, et al.
Publicado: (2019)

Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined Hypoxia and Pulmonary Inflammation
por: Chabert, Clovis, et al.
Publicado: (2018)

Inhibition of Osteoclastogenesis and Inflammatory Bone Resorption by Targeting BET Proteins and Epigenetic Regulation
por: Park-Min, Kyung-Hyun, et al.
Publicado: (2014)

Bromodomain inhibitor I‐BET151 suppresses immune responses during fungal–immune interaction
por: Domínguez‐Andrés, Jorge, et al.
Publicado: (2019)

Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells
por: Quintela, Marcos, et al.
Publicado: (2023)

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
por: Falcinelli, Shane D., et al.
Publicado: (2022)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice
por: Sullivan, Josefa M., et al.
Publicado: (2015)

Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis
por: Wang, Zhong-Yi, et al.
Publicado: (2021)

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
por: Luo, Yi, et al.
Publicado: (2021)

Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis
por: Kozumi, Kazuhiro, et al.
Publicado: (2021)

The plasma degradome reflects later development of NASH fibrosis after liver transplant
por: Li, Jiang, et al.
Publicado: (2023)

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
por: Wyce, Anastasia, et al.
Publicado: (2013)

The Crosstalk Between Liver Sinusoidal Endothelial Cells and Hepatic Microenvironment in NASH Related Liver Fibrosis
por: Du, Wei, et al.
Publicado: (2022)

Effect of Roux-en-Y Gastric Bypass Surgery on Bile Acid Metabolism in Normal and Obese Diabetic Rats
por: Bhutta, Hina Y, et al.
Publicado: (2015)

Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
por: Traber, Peter G., et al.
Publicado: (2013)

Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration
por: Mander, Palwinder, et al.
Publicado: (2005)

Essential oil components of turmeric inhibit hepatic lipidification and liver fibrosis in a diet-induced NASH model rats
por: Watanabe, Yukari, et al.
Publicado: (2023)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
por: Stefano, J.T., et al.
Publicado: (2015)

Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH
por: Bruschi, Francesca V., et al.
Publicado: (2020)

The Role of the Histone Methyltransferase EZH2 in Liver Inflammation and Fibrosis in STAM NASH Mice
por: Lee, Seul, et al.
Publicado: (2020)

Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH
por: Itoh, Michiko, et al.
Publicado: (2023)

Glucocorticoid-Induced Fatty Liver Disease
por: Rahimi, Leili, et al.
Publicado: (2020)

Chromatin targeting drugs in cancer and immunity
por: Prinjha, Rab, et al.
Publicado: (2013)

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
por: Goto, Ryo, et al.
Publicado: (2019)

MerTK, a risk factor for NASH fibrosis
por: Wang, Xiaobo, et al.
Publicado: (2020)

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
por: Fan, Weiguo, et al.
Publicado: (2021)

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
por: Heinemann, Anja, et al.
Publicado: (2015)

Iron-rich Kupffer cells exhibit phenotypic changes during the development of liver fibrosis in NASH
por: Kanamori, Yohei, et al.
Publicado: (2021)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
por: Eeckhoute, Jérôme
Publicado: (2022)

Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes
por: Carrieri, Patrizia, et al.
Publicado: (2022)

Characteristic gene expression in the liver monocyte-macrophage-DC system is associated with the progression of fibrosis in NASH
por: Wang, Xiaoxiao, et al.
Publicado: (2023)

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model
por: van Koppen, Arianne, et al.
Publicado: (2017)

Unraveling the Potential Role of Tecomella undulata in Experimental NASH
por: Srinivas, Akshatha N., et al.
Publicado: (2023)

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
por: O’Farrell, Marie, et al.
Publicado: (2022)

Drawing on disorder: How viruses use histone mimicry to their advantage
por: Tarakhovsky, Alexander, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_avd2vchai9e6l52civdljjnvt2